M8386
α,β-亚甲基腺苷 5′-二磷酸 钠盐
≥98% (HPLC), synthetic (organic), powder
别名:
AMP-CP
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C11H17N5O9P2
化学文摘社编号:
分子量:
425.23
UNSPSC Code:
41106305
PubChem Substance ID:
NACRES:
NA.51
MDL number:
Assay:
≥98% (HPLC)
Biological source:
synthetic (organic)
Form:
powder
Solubility:
water: 50 mg/mL, clear to slightly hazy, colorless
Storage temp.:
−20°C
产品名称
α,β-亚甲基腺苷 5′-二磷酸 钠盐, CD73 inhibitor
SMILES string
[Na].Nc1ncnc2n(cnc12)C3OC(COP(O)(=O)CP(O)(O)=O)C(O)C3O
InChI
1S/C11H17N5O9P2.Na.H/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(25-11)1-24-27(22,23)4-26(19,20)21;;/h2-3,5,7-8,11,17-18H,1,4H2,(H,22,23)(H2,12,13,14)(H2,19,20,21);;
InChI key
HEBWZOPLDYDXPJ-UHFFFAOYSA-N
biological source
synthetic (organic)
assay
≥98% (HPLC)
form
powder
solubility
water: 50 mg/mL, clear to slightly hazy, colorless
storage temp.
−20°C
Quality Level
相关类别
Application
αβ-亚甲基腺苷5′-二磷酸钠盐用作胞外核苷酸酶/CD73抑制剂，表征腺苷的产生模式 和作为 体外研究的抑制剂。
Biochem/physiol Actions
αβ-亚甲基腺苷5′-二磷酸（AMP-CP）是ADP类似物，具有抑制胞外核苷酸酶/CD73 的能力，通过CD73/胞外-5′-核苷酸酶，用于研究腺苷能信号调控。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Ischemia-driven expression of CD73 confers tissue protection during liver ischemia/reperfusion.
Charles C Caldwell et al.
Gastroenterology, 135(5), 1460-1462 (2008-10-14)
Camilla Mohlin et al.
Pharmacology, 84(4), 196-202 (2009-09-05)
Extracellular ATP may be metabolized to AMP and adenosine by the ectonucleotidases CD39 and CD73 and, in this study, we characterized the pathways for adenosine formation in human urinary tract epithelial cells. Bladder (RT4) and kidney (A498) epithelial cells were
Charles Dumontet et al.
European journal of medicinal chemistry, 157, 1051-1055 (2018-09-04)
The ecto-5'-nucleotidase CD73 has emerged as an important drug target in oncoimmunology as well as in other diseases. We describe new ADP analogues as CD73 inhibitors based on the replacement of the adenosine moiety, in the reference inhibitor APCP, by
Adenosine A3 receptor elicits chemoresistance mediated by multiple resistance-associated protein-1 in human glioblastoma stem-like cells.
Torres A
Oncotarget, 7, 67373-67386 (2016)
Jussi Niemelä et al.
European journal of immunology, 38(10), 2718-2726 (2008-10-01)
IFN-beta treatment reduces the relapse rate in MS but its mechanism of action remains incompletely understood. Our aim was to clarify the beneficial effect of IFN-beta in the treatment of MS. We assessed the influence of IFN-beta treatment on (i)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持